In the latest trading session, 0.42 million Gossamer Bio Inc (NASDAQ:GOSS) shares changed hands as the company’s beta touched 1.95. With the company’s most recent per share price at $0.88 changed hands at -$0.04 or -4.74% at last look, the market valuation stands at $198.47M. GOSS’s current price is a discount, trading about -81.82% off its 52-week high of $1.60. The share price had its 52-week low at $0.45, which suggests the last value was 48.86% up since then. When we look at Gossamer Bio Inc’s average trading volume, we note the 10-day average is 0.61 million shares, with the 3-month average coming to 887.65K.
Analysts gave the Gossamer Bio Inc (GOSS) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.60. If we narrow down to specifics, the data shows that 0 out of 10 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 3 recommended GOSS as a Hold, 7 felt it is a Buy and 0 rated the stock as Underweight. Gossamer Bio Inc’s EPS for the current quarter is expected to be -0.15.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Gossamer Bio Inc (NASDAQ:GOSS) trade information
Instantly GOSS was in red as seen in intraday trades today. With action -9.37%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -3.86%, with the 5-day performance at -9.37% in the red. However, in the 30-day time frame, Gossamer Bio Inc (NASDAQ:GOSS) is -12.27% down. Looking at the short shares, we see there were 7.75 million shares sold at short interest cover period of 8.59 days.
The consensus price target for the stock as assigned by Wall Street analysts is 4, meaning bulls need an upside of 78.0% from its recent market value. According to analyst projections, GOSS’s forecast low is 2 with 5 as the target high. To hit the forecast high, the stock’s price needs a -468.18% plunge from its current level, while the stock would need to soar -127.27% for it to hit the projected low.
Gossamer Bio Inc (GOSS) estimates and forecasts
Data shows that the Gossamer Bio Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 18.94% over the past 6 months, a 72.03% in annual growth rate that is considerably higher than the industry average of 17.20%.
Consensus estimates given by 9 financial analysts project the company’s revenue in the current quarter to hit an average of 7.7M. 9 analysts are of the opinion that Gossamer Bio Inc’s revenue for the current quarter will be 7.71M.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 11.99%. The 2024 estimates are for Gossamer Bio Inc earnings to increase by 77.55%, but the outlook for the next 5-year period is at 5.20% per year.
GOSS Dividends
Gossamer Bio Inc is expected to release its next quarterly earnings report on 2024-Nov-07.
Gossamer Bio Inc (NASDAQ:GOSS)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 2.95% of Gossamer Bio Inc shares while 81.16% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 83.63%. There are 81.16% institutions holding the Gossamer Bio Inc stock share, with NEA MANAGEMENT COMPANY, LLC the top institutional holder. As of 2024-06-30, the company held 8.0152% of the shares, roughly 18.09 million GOSS shares worth $16.3 million.
ARTAL GROUP S.A. holds the second largest percentage of outstanding shares, with 5.8958% or 13.31 million shares worth $11.99 million as of 2024-06-30.
Among Mutual Funds, the top two as of Aug 31, 2024 were Fidelity Select Portfolios – Biotechnology and Vanguard Total Stock Market Index Fund. With 7.91 shares estimated at $6.93 million under it, the former controlled 3.50% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 3.47% of the shares, roughly 7.84 shares worth around $6.86 million.
